Nemysis and Faran S.A. Sign Agreement to Cooperate for the Development of Endopeptidase E40 for Celiac Disease

Nemysis Ltd has announced a Strategic Cooperation with Faran S.A., a leading Greek pharma company, for the development and later commercialization of its E40 endopeptidase as a novel enzymatic therapy for gluten degradation.

“Faran has a longstanding tradition in bringing to the Greek market innovative products and providing innovative solutions to tackle highly prevalent unmet medical conditions. The company (Faran) has established over the years several strategic partnerships with established pharma companies from all over the world,” said Danilo Casadei Massari, Nemysis Chairman, and CEO. “We are pleased to cooperate in the late-stage development of E40, a novel enzymatic therapy for gluten degradation which will bring relief to the many patients suffering from symptoms of Celiac Disease. Faran will also be instrumental in defining the most effective route to the market for our product, which is expected to be on the market in late 2024.”

Mr. Katsikas, President & CEO of Faran, commented on the agreement, “expressing satisfaction for the new cooperation agreement which is further recognition of the key role of the company in the Greek market, spanning over 70 years of successful tradition. E40 will perfectly fit in our portfolio and complement our presence in the specific field.”